Press Releases

CatSci Ltd, an award-winning innovation partner for medicines development, along with Reach Industries, have won an Innovate UK grant to accelerate the development of life-changing oligonucleotide therapeutics. This grant will fund a collaboration that combines scientific expertise with machine vision tools to streamline the synthesis, purification and analysis of RNA medicines. Based on Lumi Visual Intelligence platform developed by Reach Industries, CatSci and Reach will build a s

Taiwan-based Formosa Pharmaceuticals announced today that the company has entered into an exclusive licensing agreement with Apotex Inc. (“Apotex”), for exclusive rights in Canada to the commercialization of clobetasol propionate ophthalmic suspension, 0.05% (APP13007), a patented innovative medicine for the treatment of inflammation and pain following ocular surgery.  Clobetasol propionate ophthalmic suspension, 0.05% (APP13007) was approved by the U.S. Food and Drug Adminis

Amylyx Pharmaceuticals, Inc. today announced the European Commission, based on a positive opinion issued by the Committee for Orphan Medicinal Products of the European Medicines Agency, has granted Orphan Drug Designation for AMX0035, Amylyx’ proprietary, fixed-dose combination of sodium phenylbutyrate (PB) and taurursodiol (TURSO; also known as ursodoxicoltaurine outside of the U.S.) for the treatment of Wolfram syndrome. Wolfram syndrome is a prototypical disease of endoplas

Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics that restore synapses to improve the lives of patients worldwide, today announced that enrollment is now open in Australia for their Phase 2 clinical trial evaluating SPG302 for the treatment of people with Alzheimer’s disease (AD), the most prevalent form of dementia worldwide. “The SPG302 trials are a completely different approach to tackling Alzheimer’s Disease,&r

Indica Labs, the leading provider of AI-powered digital pathology solutions, proudly announces the launch of Lung Macrodissect AI, a groundbreaking tool that revolutionizes slide macrodissection and molecular pathology workflows. Lung Macrodissect AI represents a significant leap forward for the integration of artificial intelligence with digital pathology by offering pathologists a streamlined macrodissection workflow that minimizes human error and improves efficiency.   Tumor

Bio-Techne Corporation is pleased to announce the launch of the Leo™ System. This next-generation Simple Western™ instrument offers higher throughput, flexibility, and efficiency over the current Jess™ and Abby™ Simple Western Systems. This state-of-the-art instrument enables simultaneous processing of up to 100 samples in a single 3-hour run, allowing scientists to process more samples in a day. Leo also provides 4-times the experimental size of Jess or Abby to facili

Freudenberg Medical, a manufacturer of medical and pharmaceutical devices, components and tubing, has expanded its biopharma product portfolio to include custom single-use assemblies which combine Freudenberg’s expertise in silicone extrusion and molding. New offerings include, but are not limited to, single-use y-connector manifolds, tubing assemblies, and bottle cap assemblies with multiple inlets/outlets. Bottlecap assemblies with y-connector tubing are commonly used in lab or cGMP b

IotaSciences, the Oxford-based leader in single-cell biology handling solutions has successfully raised an equity round in new growth funding to continue expansion of its pioneering business related to single-cell biology handling solutions. Such solutions are key to R&D workflows related Cell and Gene Therapy (CGT) and other applications and represent a multimillion dollar market potential in the coming years(1). The funding was strongly supported by existing investors, includi

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced positive clinical data from the first dose cohort (5 mg/kg) of PGN-EDO51, its lead investigational candidate for patients with Duchenne muscular dystrophy (DMD) whose mutations are amenable to an exon 51-skipping approach. In the ongoing CONNECT1-EDO51 Phase 2

Advantage Therapeutics today announced groundbreaking results from a study on AD04™, a novel therapeutic candidate for Alzheimer's disease. Scientists from ADvantage presented the research poster "AD04™ - modifying Alzheimer’s disease by modulation of hippocampal lipid metabolism" at the Alzheimer’s Association International Conference, Key Findings: Pleiotropic Activity: Clinical and proteomics-based studies d